... of GDP by 2030. Investments in technology are already yielding results: over the past two years, the number of applications for patent registrations has increased by 13%, indicating a growth in innovative activity. The president noted the success of Russian companies in creating new brands and products. Just last year, entrepreneurs registered 77,000 new trademarks—a 12% increase over the previous year. In total, there are approximately 1,000,000 active trademarks in the country. The government aims to ...

... forced German companies to suspend or stop their activities in the region. However, Ulf Schneider argues that the German automotive sector has suffered more from these restrictions than it has gained. In the absence of European manufacturers, Chinese companies have been rapidly capturing the Russian market, offering increasingly competitive models at attractive prices. Schneider believes that the return of brands like BMW and Mercedes would help balance the market, offering Russian consumers a European alternative to Chinese brands and restoring ...

... liquidity, and limited experience using this instrument. Nevertheless, the international trend and interest in alternative methods for going public may foster the development of SPAC in the country. Looking ahead, SPAC could become an attractive option for Russian companies, particularly in the tech sector, if market conditions improve and corresponding legislative changes are enacted. SPAC has become a popular method for going public due to its flexibility, expedited process, and potential for attracting experienced ...

Discussing the growing competition for Russian oil in Europe. What implications might this have for the market and prices? The EU has politically positioned itself against Russian energy resources, yet Hungary and Serbia continue to develop long-term plans for their procurement. Specifically,...

... Sistema), known for producing “Sputnik V” and a wide range of drugs and dietary supplements, is also preparing for an IPO: its revenue in 2023 amounted to 32.5 billion rubles, and the company's strategists emphasize growing investor interest in Russian pharmaceutical assets. Another example is “Ozon Pharmaceuticals”—a generic manufacturer from the Samara region—that announced IPO plans for the fall of 2024. In the narrower biotech segment, companies like “Betuvax” (vaccine “Betuvax-CoV-2”) and “Promomed” are mentioned; although they are more focused on biopharmaceuticals, their IPOs demonstrate a general interest in profile assets. The IPO strategy for such companies typically ...